ArticleMolecular cancer therapeutics2019
Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis.
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- miRNA-Based Therapeutics in Breast Cancer: A Systematic Review.Frontiers in oncology · 2021Pooled it
- MicroRNAs in Breast Cancer: Biological Functions and Technologies for Experimental and Therapeutic Applications.Cancers · 2026Review
- The dual facets of MiRNA in modulating NF-κB in breast cancer.Cancer cell international · 2025Review
- Stemness of Cancer: A Study of Triple-negative Breast Cancer From a Neuroscience Perspective.Stem cell reviews and reports · 2025Review
- Prospects and Challenges of Different Delivery Systems in Breast Tumors Therapy.Breast cancer : basic and clinical research · 2025Review
- Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024Review
- Review
- Genetic variations in tumor-suppressor miRNA-encoding genes and their target genes: focus on breast cancer development and possible therapeutic strategies.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- The Role of MicroRNAs in Breast Cancer and the Challenges of Their Clinical Application.Diagnostics (Basel, Switzerland) · 2023Review
- Combating breast cancer progression through combination therapy with hypomethylating agent and glucocorticoid.iScience · 2023Article
- The various role of microRNAs in breast cancer angiogenesis, with a special focus on novel miRNA-based delivery strategies.Cancer cell international · 2023Review
- Article
- Gold Nanoparticles in Triple-Negative Breast Cancer Therapeutics.Current medicinal chemistry · 2023Review
- Review
- Gold Nanoconjugates for miRNA Modulation in Cancer Therapy: From miRNA Silencing to miRNA Mimics.ACS materials Au · 2022Review
- Integration of TE Induces Cancer Specific Alternative Splicing Events.International journal of molecular sciences · 2022Review
- Review
- ST08 Altered NF-κB Pathway in Breast Cancer CellsFrontiers in oncology · 2022Article
- Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.Current research in pharmacology and drug discovery · 2022Review
- Horseradish Peroxidase-Functionalized Gold Nanoconjugates for Breast Cancer Treatment Based on Enzyme Prodrug Therapy.International journal of nanomedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Triple-negative breast cancer (TNBC) patients exhibit the worst clinical outcome due to its aggressive clinical course, higher rate of recurrence, and a conspicuous lack of FDA-approved targeted therapies. Here, we show that multilayered nanoparticles (NPs) carrying the metastasis suppressor microRNA miR-708 (miR708-NP) localize to orthotopic primary TNBC, and efficiently deliver the miR-708 cargo to reduce lung metastasis. Using a SOX2/OCT4 promoter reporter, we identified a population of miR-708
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.